Carborane-Based Tebufelone Analogs and Their Biological Evaluation In Vitro

Area of Science:

• Oncology
• Medicinal Chemistry
• Biochemistry

Background:

• Cancer-related inflammation involves mediators like cytokines and eicosanoids.
• Targeting inflammatory pathways presents a viable cancer treatment strategy.
• Eicosanoids are synthesized by key enzymes cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO).

Purpose of the Study:

• To design and synthesize novel carborane-containing analogs of the dual COX-2/5-LO inhibitor tebufelone.
• To evaluate the in vitro inhibitory activity of these analogs against COX and 5-LO enzymes.
• To assess the antiproliferative and anticancer effects of the most promising compounds in colon adenocarcinoma cells.

Main Methods:

• Incorporation of metabolically stable, hydrophobic dicarba-closo-dodecaboranes (carboranes) into the tebufelone scaffold.
• Synthesis of eight carborane-based tebufelone analogs.
• In vitro enzyme inhibition assays for COX and 5-LO.
• Cell viability studies using HT29 colon adenocarcinoma cells.

Main Results:

• Carborane-tebufelone analogs exhibited no COX inhibition but demonstrated significant 5-LO inhibitory activity in vitro.
• Para-carborane analogs, particularly those with chain elongation and a methylene spacer, showed enhanced antiproliferative effects.
• These modified analogs displayed higher anticancer activity compared to the parent compound, tebufelone.

Conclusions:

• The strategy of incorporating carboranes into tebufelone is effective for designing potent 5-LO inhibitors.
• Modified carborane-tebufelone analogs show significant potential as cytostatic agents for cancer therapy.
• This approach offers a promising avenue for developing novel anticancer therapeutics targeting 5-LO pathways.